Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurora SpineASAPF -1.56%36 3-Year Revenue Growth Rate is 2.40% as of Jun. 2026, which is at its 10-year median of 2.40. GuruFocus rates ASAPF with a GF Score™ of 36/100 and a GF Value™ of $0.21 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Aurora Spine ranks worse than 53.96% on this metric.
During the past 12 months, Aurora Spine's average Revenue per Share Growth Rate was -6.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 2.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 9.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 2.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Aurora Spine was 16.30% per year. The lowest was -6.00% per year. And the median was 2.40% per year.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Aurora Spine 3-Year Revenue Growth Rate Related Terms
ASAPF vs ABT, SYK, MDT: 3-Year Revenue Growth Rate Comparison
For the Medical Devices subindustry, Aurora Spine's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurora Spine 3-Year Revenue Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aurora Spine's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Aurora Spine's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 2.40% mean?
Aurora Spine (ASAPF) has a 3-Year Revenue Growth Rate of 2.40% as of Jun. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Aurora Spine and its competitors. This is near median its historical median of 2.40. According to the industry distribution chart, Aurora Spine ranks #409 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 54%.
Is Aurora Spine's 3-Year Revenue Growth Rate too high?
Aurora Spine's current 3-Year Revenue Growth Rate of 2.40% is near median its 10-year median of 2.40. The Medical Devices & Instruments industry median 3-Year Revenue Growth Rate is 3.75. Aurora Spine's value of 2.40% is 36% below this industry median. Based on the distribution chart, Aurora Spine ranks #409 out of 758 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Aurora Spine has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aurora Spine's 3-Year Revenue Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aurora Spine ranks #409 out of 758 companies for 3-Year Revenue Growth Rate. This places Aurora Spine in the lower half of its industry. The industry median 3-Year Revenue Growth Rate is 3.75. Aurora Spine's value of 2.40% is 36% below this benchmark. While the company's 10-year median is 2.40 vs. the industry median of 3.75, Aurora Spine has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Revenue Growth Rate among Medical Devices & Instruments companies is 3.75, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurora Spine's current 3-Year Revenue Growth Rate of 2.40% is 36% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Aurora Spine and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Revenue Growth Rate is 3.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurora Spine's current 3-Year Revenue Growth Rate is 2.40%, which is near median its own 10-year median of 2.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurora Spine stock overvalued right now?
Based on GuruFocus' analysis, Aurora Spine (ASAPF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.21, compared to a current price of $0.11 — trading 48.8% below its estimated fair value. The current 3-Year Revenue Growth Rate is 2.40%, which is near median its 10-year median of 2.40 and 36% below the Medical Devices & Instruments industry median of 3.75. Aurora Spine's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Aurora Spine (ASAPF), the current 3-Year Revenue Growth Rate is 2.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurora Spine (ASAPF) Overvalued in 2026?
Based on GuruFocus' analysis, Aurora Spine stock appears to be undervalued.
The current stock price of $0.11 is trading 48.8% below its estimated GF Value™ of $0.21.
GuruFocus considers Aurora Spine to be Possible Value Trap.
Key valuation signals for ASAPF:
3-Year Revenue Growth Rate: 2.40% (near median its 10-year median of 2.40)
GF Value™: $0.21 vs. price of $0.11 (48.8% below fair value)
Industry Position: 36% below the Medical Devices & Instruments median (#409 of 758)
No single metric tells the full story. See the ASAPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurora Spine Corp is engaged in the development, manufacture, and sale of minimally invasive, interspinous fusion systems and devices. These 510K and patent protected medical devices improve patient outcomes in the area of spine and sacroiliac joint surgical procedures. The company is focused on bringing new solutions to the spinal implant market through a series of minimally invasive, regenerative spinal implant technologies.
36GF Score
Get the complete analysis for ASAPF
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASAPF has been successfully added to your 
